Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABER: mFOLFIRINOX +/- SBRT in Pancreatic Cancer
NCT04986930Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Aug 2021
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Asan Medical Center. Primary endpoint: 1-year progression-free survival rate. Started Aug 2021; status: active, not recruiting.
Beyond the preview
Go deeper on NCT04986930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986930.